Richter & Hetero Labs Partner on Generic of Ozempic in Hungary
- 11 Jun 2026 7:34 AM
Hungarian pharmaceutical company Gedeon Richter on Wednesday announced the signing of a global collaboration agreement with Indian peer Hetero Labs on the joint development, registration and commercialisation of a semaglutide injection, a generic of the anti-diabetic drug Ozempic.
Hetero Labs has already made "significant" development investments, including technology setup and registration batch manufacturing, Richter said.
Regulatory filings are underway, with European Union and United States submissions planned for 2027, it added.
The collaboration leverages Hetero Labs' market reach in the United States and emerging markets, as well as Richter's commercial infrastructure across Europe and Central Asia, while maintaining optionality for future European manufacturing by Richter.
More:
gedeonrichter.com/en
Photo: Richter
Source: MTI – Hungary’s national news agency since 1881.
*********************************************************************************************
You're very welcome to comment, discuss and enjoy more stories via our Facebook page:
Facebook.com/XpatLoopNews + via XpatLoop’s groups: Budapest Expats / Expats Hungary
You can subscribe to our newsletter here: XpatLoop.com/Newsletters
Showcase Your Business to Expats in the Loop:
As an independent portal we’re grateful to all commercial supporters who help keep you in the loop with fresh insights and inspiration. Do you want your business to reach tens of thousands of potential high-value expat customers? If so please contact us here.
LATEST NEWS IN health & wellness